This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish (read more).

Resources - Webinars

Speed, Quality & Cost – Why You Should be Conducting Your Clinical Trials in Australia – A PCI Clinical Services Webinar

Why You Should be Conducting Your Clinical Trials in Australia.

Over the last 20 years, Australia has grown to become a destination of choice for the conduct of early phase clinical trials. Rapid ethics approval and a simple notification to the Therapeutic Goods Administrations (TGA) means that from submission to FPFD it will only take on average 6 weeks. Coupled with the attractive R&D tax incentive program offered by the Australian Government, this swift pathway to study data can then be used to support an IND or IMPD application allowing companies to speed up their drug development process.

View the webinar today

Watch the video by filling in the form below...

 

Watch PCI Clinical Services and their partners for this educational webinar to learn more and understand:

  1. The specific considerations required for Phase I trial design in Australia.
  2. Australia’s R&D tax incentive program and eligibility when conducting your trials in Australia.
  3. The specific requirements for importing, manufacturing, compounding and labelling your product for Australian clinical studies.

Speakers:

Cameron Johnson, Chief Executive Officer and Managing Director, Nucleus Network Ltd.

Cameron Johnson joined Nucleus Network in August 2013 as the Chief Operating Officer, before moving into the position of Managing Director. Prior to joining Nucleus Network, Cameron held the position of Chief Executive Officer at a Phase 1 Clinical Trials Organisation and was also the inaugural CEO of the company. Cameron has worked in early phase clinical trials organisations across Australia and Europe since 2001.

Craig Rogers, SVP of Asia Pacific, PCI Clinical Services.

Craig has over 20 years of experience working within the pharmaceutical industry. This included roles in Regulatory Affairs at big pharma and local biotech; Scientific Affairs at IDT; and General Manager at both CMAX and Nucleus Network Phase I clinical units. In 2008, Craig established PPP, based on his gap analysis of the services available in the local market, to support clinical trial manufacturing and logistics. Craig is a registered pharmacist, toxicologist and lawyer.

Simone Quin, Partner, Prime Accounting and Business Advisory Services.

Simone has over 20 years of experience in the business management of science and research, including positions within universities, government, collaborative research centres and in consulting. Simone has a Bachelor of Commerce degree from the University of Melbourne and a Graduate Certificate in Science and Technology Commercialisation from Adelaide University; a Graduate Diploma in Applied Corporate Governance and is a member of the Institute of Chartered Accountants.

What You Will Learn

Watch PCI Clinical Services and their partners for this educational webinar to learn more and understand:

  1. The specific considerations required for Phase I trial design in Australia
  2. Australia’s R&D tax incentive program and eligibility when conducting your trials in Australia
  3. The specific requirements for importing, manufacturing, compounding and labelling your product for Australian clinical studies

November 19, 2018


PCI Clinical Services to Showcase Expertise in Phase I Clinical Trials in Australia

PCI will showcase our expertise in Phase I Clinical Trials in Australia with a series of West Coast US seminars... View Article

Success at Aspire Blaenau Gwent Shared Apprenticeship Awards

PCI is celebrating two wins in the Aspire Blaenau Gwent Shared Apprenticeship Program Awards 2018. PCI as an organization and... View Article

x